Bronchostop - instructions for use, dose, side effects, contraindications

Excipients: propylene glycol 1000 mg, sorbitol (sorbitol) - 50 mg, citric acid monohydrate 5.0 mg, sodium saccharinate - 5.0 mg, sodium benzoate - 2.5 mg, vanillin - 2.5 mg, water purified to 5 ml.

Description:

Transparent, colorless or slightly yellowish liquid with a smell of vanillin.

Pharmacotherapeutic group:Expectorant mucolytic agent

ATX: & nbsp

R.05.C.B Mucolytics

R.05.C.B.02 Bromhexine

Pharmacodynamics:

The drug has mucolytic (secretolitic), expectorant weak antitussive effect. Reduces the viscosity of sputum (depolymerizes mukoproteinovye and mucopolysaccharide fibers, increases the serous component of the bronchial secretion); activates ciliated epithelium, increases volume and improves sputum discharge.Stimulates the production of endogenous surfactant, which ensures the stability of alveolar cells in the process of breathing. The effect is manifested after 2-5 days from the beginning of treatment.

Pharmacokinetics:

When ingested almost completely (99%) is absorbed in the gastrointestinal tract for 30 minutes. Bioavailability is about 80%. It penetrates the placental barrier and the blood-brain barrier. In the liver it is demethylated and oxidized, metabolized to pharmacologically active ambroxol. The highest concentration in the plasma is achieved 1 h after the administration of bromhexine hydrochloride. Half-life (T1 / 2) - 12 hours (due to slow back diffusion from tissues). It is excreted by the kidneys. Unchanged in the urine, only a small amount of the drug is released. With chronic renal failure, the release of metabolites is disrupted. With multiple applications can cumulate.

Indications:

Acute and chronic lung diseases, accompanied by the formation of sputum of increased viscosity (bronchial asthma, cystic fibrosis, pulmonary tuberculosis, pneumonia, trachebronchitis, bronchitis of different etiology (including complicated by bronchiectasis).

Sanitation of the bronchial tree in the preoperative period and during the medical and diagnostic intrabronchial manipulation, prevention of congestion in the bronchi of thick viscous sputum after the operation.

Contraindications:

hypersensitivity to the drug component;
hereditary intolerance to fructose (due to the presence of sorbitol in the formulation);
peptic ulcer of the stomach;
stomach ulcer;
pregnancy (I trimester);
lactation period.

Carefully:

Renal and / or liver failure; bronchial diseases, accompanied by excessive accumulation of secretion, in the anamnesis - gastric bleeding.

Pregnancy and lactation:

The drug is contraindicated in the first trimester of pregnancy and during lactation.

From the 4th month of pregnancy the drug is used only as prescribed by the doctor.

If it is necessary to use the drug, breastfeeding should be discontinued.

Dosing and Administration:

Inside, regardless of food intake.

Adults and children over 14 years of age - 8-16 mg 3-4 times a day.

Children under 2 years - 2 mg 3 times a day, 2 to 6 years - 2-4 mg 3 times a day, from 6 to 14 years - 4-8 mg 3 times a day.

Side effects:

Rarely for prolonged use of the drug are possible: dizziness, headache, dyspepsia, including nausea, vomiting; exacerbation of peptic ulcer of the stomach and duodenum, allergic reactions (skin rash, face swelling, rhinitis, etc.), increased activity of "liver" transaminases in the blood serum.

In these cases, the drug should be discontinued.

Overdose:

Symptoms: dyspeptic disorders, incl. nausea, vomiting, diarrhea.

Treatment: artificial vomiting, gastric lavage (in the first 1-2 hours after administration).

Interaction:

The drug is not prescribed simultaneously with drugs that suppress the cough center (including codeine), as this makes it difficult to escape the diluted sputum (accumulation of bronchial secretions in the airways).

Incompatible with alkaline solutions.

Promotes the penetration of antibiotics (amoxicillin, erythromycin, cephalexin, oxytetracycline), sulfonamide drugs in the bronchial secret in the first 4-5 days of antimicrobial therapy.

Joint use of the drug with some non-staged anti-inflammatory drugs (for example, salicylates, phenylbutazone or butadione) can cause irritation of the gastric mucosa.

Special instructions:

Bromhexine should be taken with caution weakened patient.

In the course of treatment, it is recommended to use a sufficient amount of liquid that, while maintaining the secretolitic action of bromhexine, increases its expectorant effect.

In children, treatment should be combined with postural drainage or vibration massage of the chest, facilitating the evacuation of secretions from the bronchi.

Effect on the ability to drive transp. cf. and fur:There is no information about the unfavorable effect of the drug on the ability to drive vehicles and service mechanisms that require a high concentration of attention and speed of psychomotor reactions.

Form release / dosage:

Syrup 4 mg / 5 ml.

Packaging:

100 ml in polymer bottles.

100 ml in bottles of dark glass.

Each vial with the instructions for use, complete with a spoon of a polymer or a measuring cup, is placed in a pack of cardboard.

Storage conditions:

In the dark place at temperature not higher than 25 ° С.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date indicated on the package.

Terms of leave from pharmacies:Without recipe

Registration number:LP-002072

Date of registration:23.05.2013 / 07.09.2015

Expiration Date:23.05.2018

The owner of the registration certificate:SLAVYANSKAYA APTEKA, LLC SLAVYANSKAYA APTEKA, LLC Russia

Manufacturer: & nbsp

SLAVYANSKAYA APTEKA, LLC Russia

Information update date: & nbsp07.03.2017

Illustrated instructions

Instructions

Bronchostop (Broncchostop)